Authors
Zeljko Vujaskovic, Dong W Kim, Ellen Jones, Lan Lan, Linda McCall, Mark W Dewhirst, Oana Craciunescu, Paul Stauffer, Vlayka Liotcheva, Allison Betof, Kimberly Blackwell
Publication date
2010/8/1
Journal
International Journal of Hyperthermia
Volume
26
Issue
5
Pages
514-521
Publisher
Taylor & Francis
Description
Purpose: The prognosis for locally advanced breast cancer (LABC) patients continues to be poor, with an estimated five-year survival of only 50–60%. Preclinical data demonstrates enhanced therapeutic efficacy with liposomal encapsulation of doxorubicin combined with hyperthermia (HT). Therefore this phase I/II study was designed to evaluate the safety and efficacy of a novel neoadjuvant combination treatment of paclitaxel, liposomal doxorubicin, and hyperthermia.
Materials and methods: Eligible patients received four cycles of neoadjuvant liposomal doxorubicin (30–75 mg/m2), paclitaxel (100–175 mg/m2), and hyperthermia. They subsequently underwent either a modified radical mastectomy or lumpectomy with axillary node dissection followed by radiation therapy and then eight cycles of CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy.
Results: Forty-seven patients with stage IIB-III …
Total citations
Scholar articles
Z Vujaskovic, DW Kim, E Jones, L Lan, L McCall… - International Journal of Hyperthermia, 2010